5JA1.F Sprint Bioscience AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.3200 EUR
Close of Nov 11, 2026
0.0380 0.3850
Market cap
EUR 33.8M
P/E
5.3x
P/B
4.50x
ROE
-64.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5JA1.F undervalued?

Graham number
Price0.3200
Graham value0.3100
Premium3.2%

5JA1.F trades 3.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sprint Bioscience AB (publ) fundamental analysis

No fundamental analysis for Sprint Bioscience AB (publ) yet.

Sprint Bioscience AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sprint Bioscience AB (publ)

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherap…

Full company profile